Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug
Eli Lilly’s Obesity Pill Orforglipron Challenges Novo Nordisk’s Oral Wegovy in Weight-Loss Market Race August 24, 2025 The obesity drug market, projected to surpass $73 billion by 2034, is witnessing a fierce competition between pharmaceutical giants Eli Lilly and Novo Nordisk. Eli Lilly’s oral GLP-1 receptor agonist, orforglipron, is emerging as a significant rival to … Read more